Sanofi Q4 Results Rise; Sees Growth In FY22 Business EPS

French drug major Sanofi reported Friday higher profit and net sales in its fourth quarter, mainly benefited by strong sales growth of Dupixent, despite weakness in Vaccines and General Medicines. Specialty Care advanced to the largest business unit by sales. Looking ahead for fiscal 2022, Sanofi expects business earnings per share to grow low double-digit at constant exchange rates.

from RTT - Top Story https://ift.tt/f4bYL9J
via IFTTT